UY38933A - Vacuna de partículas tipo virus del chicunguña y métodos para su uso - Google Patents

Vacuna de partículas tipo virus del chicunguña y métodos para su uso

Info

Publication number
UY38933A
UY38933A UY0001038933A UY38933A UY38933A UY 38933 A UY38933 A UY 38933A UY 0001038933 A UY0001038933 A UY 0001038933A UY 38933 A UY38933 A UY 38933A UY 38933 A UY38933 A UY 38933A
Authority
UY
Uruguay
Prior art keywords
virus
chicunguña
methods
type particulate
vaccine
Prior art date
Application number
UY0001038933A
Other languages
English (en)
Inventor
Robert BENNETT Sean
Fowler Smith Jonathan
L Alexander Jeffery
Original Assignee
Emergent Travel Health Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Emergent Travel Health Inc filed Critical Emergent Travel Health Inc
Publication of UY38933A publication Critical patent/UY38933A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5258—Virus-like particles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55505—Inorganic adjuvants
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/36011—Togaviridae
    • C12N2770/36111—Alphavirus, e.g. Sindbis virus, VEE, EEE, WEE, Semliki
    • C12N2770/36123—Virus like particles [VLP]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/36011—Togaviridae
    • C12N2770/36111—Alphavirus, e.g. Sindbis virus, VEE, EEE, WEE, Semliki
    • C12N2770/36134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/36011—Togaviridae
    • C12N2770/36111—Alphavirus, e.g. Sindbis virus, VEE, EEE, WEE, Semliki
    • C12N2770/36171—Demonstrated in vivo effect
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Molecular Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Genetics & Genomics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Dermatology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicinal Preparation (AREA)

Abstract

La presente divulgación se refiere a composiciones y vacunas de partículas tipo virus (VLP) mejoradas para usar en la inducción de una respuesta inmunitaria y/o inmunidad protectora contra una infección del virus del chicunguña (CHIKV) en un sujeto, por ejemplo, mediante la inducción de una respuesta de anticuerpo neutralizante contra CHIKV en un sujeto dentro de los 7 días después de la administración de una dosis única de la composición o vacuna.
UY0001038933A 2019-10-25 2020-10-26 Vacuna de partículas tipo virus del chicunguña y métodos para su uso UY38933A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201962926357P 2019-10-25 2019-10-25
US202062993563P 2020-03-23 2020-03-23

Publications (1)

Publication Number Publication Date
UY38933A true UY38933A (es) 2021-04-30

Family

ID=75620856

Family Applications (1)

Application Number Title Priority Date Filing Date
UY0001038933A UY38933A (es) 2019-10-25 2020-10-26 Vacuna de partículas tipo virus del chicunguña y métodos para su uso

Country Status (13)

Country Link
US (1) US20220409717A1 (es)
EP (1) EP4048306A4 (es)
JP (1) JP2022553299A (es)
KR (1) KR20220097422A (es)
CN (1) CN114828881A (es)
AU (1) AU2020370603A1 (es)
BR (1) BR112022007474A2 (es)
CA (1) CA3155315A1 (es)
IL (1) IL292433A (es)
MX (1) MX2022004869A (es)
TW (1) TW202120123A (es)
UY (1) UY38933A (es)
WO (1) WO2021081499A1 (es)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN109536464B (zh) * 2018-12-10 2022-06-10 中国科学院武汉病毒研究所 一种缺失衣壳蛋白基因的基孔肯雅病毒感染性克隆及构建方法和在制备减毒疫苗中的应用

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8865184B2 (en) * 2006-09-01 2014-10-21 Bharat Biotech International Limited Vaccine for chikungunya virus infection
US9353353B2 (en) * 2008-11-26 2016-05-31 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Virus-like particles (VLPs) prepared from chikungunya virus structural proteins
WO2019016756A1 (en) * 2017-07-21 2019-01-24 Glaxosmithkline Biologicals Sa ANTIGEN CONSTRUCTS OF CHIKUNGUNYA VIRUSES

Also Published As

Publication number Publication date
IL292433A (en) 2022-06-01
EP4048306A4 (en) 2024-03-27
EP4048306A1 (en) 2022-08-31
BR112022007474A2 (pt) 2022-07-12
KR20220097422A (ko) 2022-07-07
AU2020370603A1 (en) 2022-05-12
MX2022004869A (es) 2022-07-27
US20220409717A1 (en) 2022-12-29
JP2022553299A (ja) 2022-12-22
CA3155315A1 (en) 2021-04-29
CN114828881A (zh) 2022-07-29
TW202120123A (zh) 2021-06-01
WO2021081499A1 (en) 2021-04-29

Similar Documents

Publication Publication Date Title
MX2021006931A (es) Antigenos del virus de la inmunodeficiencia humana, vectores, composiciones y metodos de uso de estos.
PH12021550479A1 (en) Dengue vaccine unit dose and administration thereof
CO2018003460A2 (es) Vacunas de partículas tipo virus (vlp) contra el parvovirus canino (cpv) y sus usos
AR108829A1 (es) Vacuna contra virus de bronquitis infecciosa
AR080111A1 (es) Metodos y composiciones de inmunizacion
WO2017214596A8 (en) Compositions and methods for preventing and treating zika virus infection
CL2016002402A1 (es) Composiciones inmunológicas que contiene histophilus somni atenuado
BR112015017966A2 (pt) composições imunogênicas compreendendo vírus silificado e métodos de uso
CU20180025A7 (es) Proceso de preparación de una vacuna tetravalente atenuada contra el virus del dengue
PH12018500305A1 (en) Multivalent vlp conjugates
PH12018501368A1 (en) M hyo multivalent vaccine and uses thereof
PE20170429A1 (es) Vacuna en vector recombinante de adenovirus aviar serotipo 9
PH12018501750A1 (en) Porcine reproductive and respiratory syndrome vaccine virus
AR121292A1 (es) Vacuna contra hpv
UY38933A (es) Vacuna de partículas tipo virus del chicunguña y métodos para su uso
CL2020002876A1 (es) Vacuna contra la bronquitis infecciosa (divisional de la solicitud no. 201803420)
AR115070A1 (es) Células madre que comprenden un virus vacuna quimérico sintético y métodos para su uso
CL2021003447A1 (es) Virus para vacuna contra el síndrome respiratorio y reproductivo porcino
AR120296A1 (es) Vacuna de partículas de virus de tipo chikungunya y sus métodos de uso
UY31574A1 (es) Vacunas contra la malaria
GT201400199A (es) Virus de la enfermedad de marek modificado y vacunas elaboradas con él
WO2018056528A3 (ko) 인플루엔자 b 백신
AR109291A1 (es) Clon de adnc del virus del síndrome reproductivo y respiratorio porcino y usos del mismo
MY192396A (en) An influenza a vaccine
PH12020550948A1 (en) Vaccines against hendra and nipah virus infection